Consulting with PARKINSUN as commu… for Parkinson's (NCT04179695)
Help patients express priorities clearly
- Trial ID
- NCT04179695
- Official Title
- Optimizing PD Patient's Health Pathways: Favoring Global, Patient Centered Care by a New Communication Aid Tool PARKINSUN
- Goal
- Help patients express priorities clearly
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- University Hospital, Lille
- Study Type
- INTERVENTIONAL
- Enrollment
- 120 participants
- Conditions
- Parkinson's Disease
- Interventions
- Consulting with PARKINSUN as communication aid-tool, Consulting without PARKINSUN as communication aid-tool
Summary For Families
The goal is to make Parkinson's care more global and patient centered by improving how patients and clinicians talk about symptoms, priorities, and care plans during visits. The approach uses a communication aid called PARKINSUN during consultations, it prompts and structures patients' symptoms, concerns, and goals, creates a clear summary to help clinicians prioritize issues and guide shared decision making, and is compared to usual consultations without the tool. Adults 18 to 90 with Parkinson's at any stage who can consent and attend visits, have no severe other neurological or psychiatric disease, score above 22 on the MOCA, speak French, and have social security coverage are eligible; people under guardianship or unable to complete the study are excluded.
Locations
- Hopital Roger Salengro, CHU Lille, Lille, France
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Consulting with PARKINSUN as communication aid-tool. The goal is to make Parkinson's care more global and patient centered by improving how patients and clinicians talk about symptoms, priorities, and care plans during visits. The approach uses a communication aid called PARKINSUN during consultations, it prompts and structures patients' symptoms, concerns, and goals, creates a clear summary to help clinicians prioritize issues and guide shared decision making, and is compared to usual consultations without the tool. Adults 18 to 90 with Parkinson's at any stage who can consent and attend visits, have no severe other neurological or psychiatric disease, score above 22 on the MOCA, speak French, and have social security coverage are eligible; people under guardianship or unable to complete the study are excluded.
- Who can participate?
- Participants must be between 18 Years and 90 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- You are never charged a fee to join a legitimate clinical trial, and the study treatment and study-specific tests are provided by the trial sponsor at no charge. In the US, routine care you would receive anyway can still be billed to you or your insurance; coverage rules differ by country, and trials in the UK and Canada usually run through public health systems. Travel, parking, and time are real costs, and some trials reimburse them while others do not. Before enrolling, ask the study coordinator to explain in writing what is and is not covered.
- How long does the trial last?
- This trial is estimated to last approximately 6 years and 4 months.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.
- Will I get a placebo in this trial?
- There is no placebo group. Everyone receives an active treatment; the study compares one treatment against another.
- How many visits does this trial involve?
- Patients will see their physicians every 3 months during 7 months.